# Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies

> **NCT00208923** · PHASE2 · COMPLETED · sponsor: **Emory University** · enrollment: 55 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Busulfan, Cyclophosphamide and Fludarabine

## Key facts

- **NCT ID:** NCT00208923
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-07
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2012-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00208923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00208923, "Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00208923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*